A dose-ranging study of the safety and efficacy of gemtuzumab ozogamicin (go) given in combination with cytarabine and daunorubicin in relapsed or refractory patients and in younger de novo patients with acute myeloid leukemia (AML).

Trial Profile

A dose-ranging study of the safety and efficacy of gemtuzumab ozogamicin (go) given in combination with cytarabine and daunorubicin in relapsed or refractory patients and in younger de novo patients with acute myeloid leukemia (AML).

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2009

At a glance

  • Drugs Cytarabine; Doxorubicin; Gemtuzumab ozogamicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Aug 2009 Actual patient number (69) added as reported by ClinicalTrials.gov.
    • 25 Aug 2009 Actual end date (September 2003) added as reported by ClinicalTrials.gov.
    • 25 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top